Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Breast Neoplasms
  • Paclitaxel

abstract

  • Paclitaxel via 3-hour infusion, without prophylactic G-CSF, is active and safe as initial and subsequent therapy for metastatic breast cancer. The transient visual symptoms noted at higher doses seem unrelated to peak plasma paclitaxel concentration. Further studies that compare 3- and 24 hour (or other) infusion schedules are necessary to determine the optimal administration of paclitaxel in metastatic breast cancer.

publication date

  • October 1995

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7595709

Additional Document Info

start page

  • 2575

end page

  • 81

volume

  • 13

number

  • 10